Actively Recruiting
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
Led by Arbeitsgemeinschaft medikamentoese Tumortherapie · Updated on 2025-04-10
500
Participants Needed
7
Research Sites
526 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.
CONDITIONS
Official Title
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older with tissue-based diagnosis of metastatic colorectal cancer
- Patients who have received at least 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (if RAS/BRAF wildtype), or anti-PD1 therapy (if MSI/MMRd)
- Patients who received mFOLFOXIRI +/- anti-VEGF or anti-EGFR as first-line therapy or those unable to receive 5-FU, oxaliplatin, or irinotecan may be included after first-line therapy
You will not qualify if you...
- No specific exclusion criteria due to the non-interventional design of this registry
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Ordensklinikum Linz, BHS - Interne I
Linz, Austria, 4010
Actively Recruiting
2
KUK Linz - Med Campus III.: Univ.-Klinik für Hämatologie und Internistische Onkologie
Linz, Austria, 4021
Actively Recruiting
3
LKH Feldkirch: Innere Medizin II/ Interne E (Hämatologie und Onkologie)
Rankweil, Austria, 6830
Actively Recruiting
4
Department of Internal Medicine III, Paracelsus Medical University Salzburg
Salzburg, Austria, 5020
Actively Recruiting
5
Klinikum Steyr: Innere Medizin II: Onkologie, Gastroenterologie, Angiologie
Steyr, Austria, 4400
Actively Recruiting
6
Klinikum Wels: Abteilung für Innere Medizin IV
Wels, Austria, 4600
Actively Recruiting
7
KH Zams: Innere Medizin Internistische Onkologie und Hämatologie
Zams, Austria, 6511
Actively Recruiting
Research Team
D
Daniela Wolkersdorfer, Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here